Naoto Yokogawa

Tokyo Metropolitan Tama Medical Center, Edo, Tōkyō, Japan

Are you Naoto Yokogawa?

Claim your profile

Publications (15)31.96 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. To validate Routine Assessment of Patient Index Data 3 (RAPID3) using a Japanese version of Multidimensional Health Assessment Questionnaire (MDHAQ) with Japanese rheumatoid arthritis (RA) patients and to describe the characteristics of RAPID3 by comparison with Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI). Methods. The original MDHAQ was translated into Japanese with minor cultural modifications and was translated back in English. Test-retest reliability was evaluated in 50 Japanese RA patients and further validation was performed in 350 Japanese RA patients recruited by seven rheumatologists. RAPID3, CDAI, and DAS28 were assessed on two consecutive visits. Results. The test-retest reliability and the internal reliability of RAPID3 were excellent. Spearman's correlation coefficients between RAPID3 score versus CDAI score and DAS28 score were 0.761and 0.555. However, the agreement measured by kappa (weighted) for RAPID3 category versus CDAI category and for RAPID3 category versus DA28 category were 0.225 (0.382) and 0.187 (0.336). The sensitivity and specificity of "RAPID3 ≤ 3 and swollen joint ≤ 1" for predicting Boolean remission were 90.0% and 93.4%, respectively. Conclusions. RAPID3 obtained by Japanese MDHAQ was validated with Japanese RA patients and the remission criteria were found to have excellent clinical utility in usual care.
    Modern Rheumatology 08/2014; · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine an appropriate focus score cutoff for childhood Sjögren syndrome (SS). Labial salivary gland tissue from specimens from children with SS and age-matched controls was retrospectively identified and reviewed by a blinded oral pathologist. The presence of any focal sialadenitis (focus score > 0 foci/4 mm(2)) was common among childhood SS samples but present in only 1 of 8 control samples. The presence of any focal lymphocytic sialadenitis in minor labial salivary gland tissue is suggestive of childhood SS and should be included in future childhood SS-specific diagnostic or classification criteria.
    The Journal of Rheumatology 05/2014; · 3.17 Impact Factor
  • Jay Mehta, Naoto Yokogawa, Scott Lieberman
    [Show abstract] [Hide abstract]
    ABSTRACT: Background/Purpose:Sjögren syndrome is a complex autoimmune disease that affects lacrimal and salivary glands along with the potential to cause damage to other organs. Diagnosis of childhood Sjögren syndrome is currently based on expert opinion due to the lack of child-specific diagnostic criteria. Children do not typically present with the sicca symptoms characteristic of adult Sjögren syndrome. While they most commonly present with recurrent parotitis, some children present with other organ involvement in the absence of parotitis. The latter may be severe requiring more extensive immunomodulatory therapy. The goal of this study was to compare serologic profiles of cohorts of children with Sjögren syndrome presenting with or without parotitis to determine if separate serology-based diagnostic criteria are needed for these two groups.Methods:We retrospectively reviewed childhood Sjögren syndrome cases from a single center as well as those in the published English literature with individual patient data. We collected available data on sicca symptoms, serologies (ANA, anti-SSA/B, RF), lacrimal and salivary gland function, imaging, and histopathology. For analyses of individual components, cases were excluded if specific data was not explicitly reported, so denominators may vary.Results:We identified 26 cases of childhood Sjögren syndrome diagnosed and followed at The Children's Hospital of Philadelphia and 67 cases in the literature that contained information on individual children. Parotitis status was reported for 82 cases and was a main feature of presentation in 59 (72%) cases. 28 of 51 (55%) children with parotitis and 13 of 22 (59%) children without parotitis presented with sicca symptoms. 53 of 58 (91%) children with parotitis and 21 of 23 (91%) children without parotitis were ANA positive. 49 of 58 (84%) children with parotitis and 20 of 23 (87%) children without parotitis were anti-SSA/B positive. 42 of 51 (82%) children with parotitis and 7 of 13 (54%) children without parotitis were RF positive. 56 of 58 (97%) children with parotitis and 22 of 23 (96%) children without parotitis were positive for either ANA or anti-SSA/B.Conclusion:A large majority (96%) of children with Sjögren syndrome have positive ANA and/or anti-SSA/B, and the serologic profiles do not significantly differ based on the presence or absence of parotitis. Thus, testing for ANA and anti-SSA/B is warranted in the diagnostic workup of any child suspected of having Sjögren syndrome, especially in patients who do not present with parotitis. Given the selection bias inherent in this approach, development of childhood Sjögren syndrome-specific diagnostic criteria are needed for future prospective studies to better characterize the prognosis and optimal therapies for this potentially devastating disease.
    Arthritis & Rheumatology. 03/2014; 66(S11).
  • Annals of the Rheumatic Diseases 01/2014; 72(Suppl 3):A843-A843. · 9.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Medical management of systemic sclerosis (SSc)-associated chronic intestinal pseudo- obstruction (CIPO) has often proved inadequate. Percutaneous endoscopic colostomy (PEC) has been proposed as a method of treatment, but it is associated with a relatively high incidence of serious complications. We report herein a very severe case of SSc-associated CIPO in which complications were successfully controlled by long tube placement via a gastrostomy. Transgastric long tube placement may offer a relatively safe alternative to PEC in treating severe SSc-associated CIPO.
    Modern Rheumatology 11/2013; · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe and compare expectations of patients with rheumatoid arthritis (RA) and their physicians with regard to what is most important to achieve during a rheumatology clinic visit. Subjects were RA patients enrolled in four centers from China, one from Japan and one from the USA, and rheumatologists at those centers. The questionnaires were provided at clinics and patients were asked to list their three top priorities for the rheumatology clinic visit. Physicians were contacted separately and asked to give three general expectations, not for specific visits. We classified clinical expectations into a series of 24 terms for patients and 17 for physicians. We compared physicians' to patients' responses, compared expectations among centers in China, Japan and the USA, and evaluated relationships between patients' responses and age, gender, nationality, disease duration and DAS-28 (Disease Activity Score-28). Patients' clinical expectations for visits focused primarily on control of pain (63.7%), improvement of function (49.3%) and discussion of effects of medication (38.1%). Physicians also included control of pain (59.5%), but also emphasized inquiry about drug side-effects (47.8%) and objective assessment of disease activity (41.4%). We found no differences related to patients' gender, disease duration and DAS-28, but there were some differences related to age and nationality. We found some agreement and some discordance of clinical expectations between RA patients and physicians. There appear to be some different expectations in different countries. Findings from this pilot survey may help physicians consider patients' expectations in planning rheumatology clinic visits and may lead to further hypothesis-driven studies.
    International Journal of Rheumatic Diseases 08/2012; 15(4):380-9. · 1.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Scleroderma renal crisis (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy. Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC. Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc. In this article, we report a patient with SRC induced by tacrolimus and corticosteroids. The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc.
    American journal of therapeutics 07/2012; · 1.29 Impact Factor
  • The Journal of Rheumatology 06/2012; 39(6):1296. · 3.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). METHODS: Twenty-seven patients with lupus-related skin disease who started HCQ at four hospitals were included. Patients were categorized into responders by the CLASI response criteria. The points and the rate of improvement in the CLASI activity score after 16 weeks of treatment were analyzed, focusing on six parameters: systemic lupus erythematosus (SLE), skin manifestations, disease duration, prednisolone, smoking, and severity. RESULTS: Twenty-seven patients, including 17 with SLE (6 with SLE/Sjögren's syndrome), were analyzed retrospectively. Twenty-three patients (85 %) were categorized as responders. The mean CLASI activity score improved from 10.1 to 4.5 (p < 0.0001). The improvement rate did not differ in these parameters except for that of annular erythema (81.6 versus 34.3 %, p = 0.036). On multivariate analysis, the baseline CLASI activity score (CLASI ≥9) correlated with the greatest decrease in CLASI activity score (F = 69.7, p < 0.0001). CONCLUSIONS: CLASI is a reliable indicator to evaluate the efficacy of the drug, and HCQ is an effective treatment for Japanese patients with lupus-related skin disease.
    Modern Rheumatology 05/2012; · 2.21 Impact Factor
  • Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases 04/2012; 18(3):159-60. · 1.19 Impact Factor
  • Naoto Yokogawa
    Nihon Naika Gakkai Zasshi 10/2011; 100(10):2960-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated the cutaneous lupus erythematosus disease area and severity index (CLASI) in Japanese patients with systemic lupus erythematosus (SLE) in order to design a clinical trial of hydroxychloroquine (HCQ) in Japan. Our prospective cohort study consisted of seven SLE patients with active skin disease who started HCQ at Tokyo Metropolitan Tama Medical Center. The therapeutic responses were assessed at 4 months. Patients were categorized as responders (improved) or non-responders (unchanged or worsened) using the criteria of a 4-point or 20% decrease in the CLASI activity score. We also assessed joint pain determined by patient visual analog scale (VAS), malaise (VAS), patient global assessment of SLE (VAS), and constitutional and musculoskeletal symptoms according to the British Isles Lupus Assessment Group (BILAG) disease activity index. Six patients (86%) were categorized as responders. The median (range) CLASI activity score of all patients at assessment had changed from 8.0 (2-22) to 4 (2-10). All five patients with joint pain and all five patients with malaise showed improvement in patient VAS but the BILAG findings failed to capture these improvements. In conclusion, the cutaneous aspects of SLE can be measured by the CLASI. The CLASI activity score may be a reasonable primary endpoint when performing a clinical trial of HCQ.
    Modern Rheumatology 08/2011; 22(2):249-55. · 2.21 Impact Factor
  • Naoto Yokogawa, Joan M. Von Feldt
    [Show abstract] [Hide abstract]
    ABSTRACT: In geriatrics, atherosclerosis is a common ­comorbidity, since aging is the strongest risk factor for its development. Patients with autoimmune rheumatic disease have an increased risk of atherosclerotic cardiovascular ­disease (ASCVD) morbidity and mortality. Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have been studied the most, but other autoimmune diseases may confer the risk of ASCVD as well. In addition to traditional risk factors, systemic inflammation likely contributes to ASCVD risk. Atherosclerosis is considered an inflammatory process, and may be accelerated by systemic inflammation. ASCVD risk reduction can be targeted by aggressive management of ASCVD risk factors and the primary rheumatic disease. KeywordsAtherosclerosis-Atherosclerotic cardiovascular disease-Endothelial dysfunction-Inflammation-Intimal-medial thickness-Morbidity-Mortality-Rheumatic ­diseases-Rheumatoid arthritis-Systemic lupus erythematosus
    12/2010: pages 17-25;
  • Naoto Yokogawa, H Ralph Schumacher
    Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases 08/2010; 16(5):250. · 1.19 Impact Factor
  • Naoto Yokogawa, Frederick B Vivino
    [Show abstract] [Hide abstract]
    ABSTRACT: We report two cases of hydralazine-induced vasculitis with rare complications: pulmonary renal syndrome and digital gangrene. We also review 68 published cases of hydralazine-induced vasculitis. Hydralazine-induced vasculitis mimics idiopathic antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis. However, it also produces other autoantibodies, such as antinuclear antibodies, antihistone antibodies, anti-dsDNA antibodies, and antiphospholipid antibodies. Patients with hydralazine-induced vasculitis typically have a more severe course than those with hydralazine-induced lupus, predominantly due to renal vasculitis, and require a more aggressive treatment.
    Modern Rheumatology 06/2009; 19(3):338-47. · 2.21 Impact Factor